Overview Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis Status: Not yet recruiting Trial end date: 2023-07-21 Target enrollment: Participant gender: Summary The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults. Phase: Phase 2 Details Lead Sponsor: Meiji Pharma USA Inc.